Retrospective study identifies ER negativity and HER-2 positivity as key factors influencing pCR in breast cancer, suggesting tailored NAC strategies.
pCR rates in breast cancer patients post-NAC vary significantly by molecular subtype. ER negativity and HER-2 positivity emerge as independent predictive factors for pCR, with ER and HER-2 exhibiting the strongest discriminative ability (AUC > 0.8). Clinicians should integrate patients' baseline clinical data, ultrasound features, and molecular markers to screen optimal NAC candidates and develop individualized strategies, thereby maximizing therapeutic benefits.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: